Kerpel-Fronius S, Gottwald M, Arányi P, Renczes G, Görbe A, Papp R, Ferdinandy P
Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary.
Independent Consultant, Berlin, Germany.
Front Pharmacol. 2024 Apr 30;15:1394987. doi: 10.3389/fphar.2024.1394987. eCollection 2024.
The pharmaceutical medicine course at the Semmelweis University of Budapest, Hungary, was initiated as part of the Innovative Medicines Initiative (IMI is the main program, IMI-PharmaTrain is one of the IMI projects) Pharmaceutical Medicine Training Programs (16 IMI Call 2008/1/16). The aim was to extend training in the development of pharmaceutical medicine to those EU member states where no such education was present. The final program envisaged the development of a cooperative education supported by universities located in Central and Eastern Europe. It was considered to be the economically and scientifically most viable approach to combine the expertise from these countries to form a united teaching staff and provide education jointly for young professionals of the region. Semmelweis University was selected to manage this coordinated program. In this report, we describe the organization and functioning of this international university-based pharmaceutical medicine education project called the Cooperative European Medicines Development Course (CEMDC) and evaluate its successes and shortcomings. During the pandemic, the educational course was interrupted. The follow-on program is reorganized as a postgraduate MSc course named "Semmelweis Pharma MBA" and will be started in 2025. It will continue the established PharmaTrain educational tradition. However, it will deal in more detail with the transition from basic pharmacological to industrial research, as well as biopharmaceutical formulation and manufacturing and marketing aspects of medicines development.
匈牙利布达佩斯塞梅维什大学的药物医学课程是作为创新药物计划（IMI是主要项目，IMI-PharmaTrain是IMI项目之一）药物医学培训项目（2008年1月16日IMI第二轮招标）的一部分启动的。其目的是将药物医学开发方面的培训扩展到那些没有此类教育的欧盟成员国。最终方案设想开展一项由中欧和东欧各大学支持的合作教育。人们认为，将这些国家的专业知识结合起来，组建一支联合教师队伍，并为该地区的年轻专业人员联合提供教育，在经济和科学上是最可行的方法。塞梅维什大学被选中管理这个协调项目。在本报告中，我们描述了这个名为欧洲药物开发合作课程（CEMDC）的以国际大学为基础的药物医学教育项目的组织和运作情况，并评估了其成败得失。在疫情期间，该教育课程中断。后续项目被重新组织为一个名为“塞梅维什药物MBA”的研究生理学硕士课程，并将于2025年启动。它将延续已确立的PharmaTrain教育传统。然而，它将更详细地探讨从基础药理学研究到工业研究的过渡，以及药物开发的生物制药配方、制造和营销方面的内容。
